喹硫平与利培酮治疗痴呆患者行为与精神障碍对照研究.docVIP

喹硫平与利培酮治疗痴呆患者行为与精神障碍对照研究 　　[摘要] 目的 研究喹硫平与利培酮治疗痴呆患者行为与精神障碍的效果。方法 方便选取该院2013年2月―2016年6月间诊疗的130例痴呆行为与精神障碍患者，按照盲选的形式，将65例患者施以喹硫平治??，设为A组；剩余65例施以利培酮治疗，设为B组，比较2组患者治疗疗效、不良反应、BEHAVE-AD评分、MMSE评分。结果 A组患者治疗总有效率为96.92%，B组患者治疗有效率为93.85%；A组患者不良反应为4.61%，B组患者不良反应为21.54%；A组患者BEHAVE-AD评分为（10.18±4.87）分、MMSE评分为（7.56±2.86）分；B组患者BEHAVE-AD评分为（16.89±5.13）分、MMSE评分为（11.71±3.23）分，即2组患者各数据比较，差异有统计学意义（P0.05）。结论 喹硫平与利培酮治疗疗效相似，但喹硫平不良反应相对较低，更适于痴呆行为与精神障碍患者，故值得推广。 　　[关键词] 喹硫平；利培酮；痴呆；行为障碍；精神障碍 　　[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2018）01（c）-0124-03 　　[Abstract] Objective This paper tries to study the effects of quetiapine and risperidone in the treatment of dementia and mental disorders. Methods Statistical analysis of 130 cases of patients with dementia behavior and mental disorder in the hospital during February 2013 to June 2016 was conducted， in accordance with the blind form， 65 patients were treated with quetiapine as group A； the remaining 65 patients were treated with risperidone as group B， compared two groups of patients with curative effect， adverse reaction， BEHAVE-AD score， MMSE score. Results The total effective rate was 96.92% in group A and 93.85% in group B. The adverse reaction was 4.61% in group A and 21.54% in group B. The BEHAVE-AD score in group A was（10.18±4.87）points， and the MMSE score was（7.56±2.86）points. The BEHAVE-AD score of group B was（16.89±5.13）points and the MMSE score was （11.71±3.23）points. There was significant statistical difference between the two groups （P0.05）. Conclusion Quetiapine and risperidone treatment are of similar efficacy， but quetiapine adverse reactions are relatively lower， more suitable for dementia behavior and mental disorders， it is worth promoting. 　　[Key words] Quetiapine； Risperidone； Dementia； Behavioral disorders； Mental disorders 　　人口老龄化的逐渐加快，促使阿尔茨海默病、脑血管病病发率显著攀升，而在痴呆患者进入某病程进展时，则80%～90%均会不同程度的行为和精神障碍，经世界老年精神病学会（1996年）将该病统称为“痴呆伴发的行为和精神症状（BPSD）”[1-2]。目前，喹硫平、利培酮均属于非典型抗精神病类药，尤其对老年痴呆患者的药效作用[3]。故该研究统计分析2013年2月―2016年6月间诊疗的130例痴呆行为与精神障